Is There a Role for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis Due to Uterine Cancer?
cytoreductive surgery
hyperthermic intraperitoneal chemotherapy
peritoneal carcinomatosis
uterine cancer
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
30 Oct 2022
30 Oct 2022
Historique:
received:
17
09
2022
revised:
17
10
2022
accepted:
26
10
2022
entrez:
29
12
2022
pubmed:
30
12
2022
medline:
30
12
2022
Statut:
epublish
Résumé
Uterine canceris one of the most common pelvic tumors in females. Advanced stage uterine cancer only represents 15% of newly diagnosed cases; however, they are related with poor prognosis. Our aim was to analyze the benefits of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis due to uterine cancer. At the Istanbul Umraniye Training and Research Hospital, Surgical Oncology Clinic, morbidity, overall survival and survival without progression were analyzed over the 5-year follow up. Twenty-two cases who had undergone cytoreductive surgery and hyperthermic intraperitoneal chemotherapy due to uterine-peritoneal carcinomatosis were included in this study. Cases were followed up in terms of postoperative morbidity-mortality, disease-free survival and overall survival. The cut off value for the peritoneal carcinomatosis index score was set at 15. Intraperitoneal chemotherapy consisting of cisplatin and doxorubicin was applied to all patients for 60 min after the suturation of the abdomen. Median age of the patients was 64.6 (43-72). Average PCI score was 12.8 (3-15). CC score was 0 in 16 (72.7%) cases, 1 in 3 cases and 2 in 3 cases. Of these patients, 12 of them were previously operated upon. Median stay at the hospital was 13.1 days. No major complications due to chemotherapy were reported. A Clavien-Dindo Grade 3 complication was observed in seven (31.8%) patients. Mortality was not observed in patients during their stay at the hospital. The 5-year disease-free survival and overall survival rates were 36.8 (36%) months and 45.3 (57%) months, respectively. We think that due to longer disease-free survival and overall survival, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be preferred in peritoneal carcinomatosis due to uterine cancer patients having low peritoneal carcinomatosis index scores and manageable complication rates. However, prospective randomizedtrials with a high number of cases are needed for this subject.
Sections du résumé
BACKGROUND
BACKGROUND
Uterine canceris one of the most common pelvic tumors in females. Advanced stage uterine cancer only represents 15% of newly diagnosed cases; however, they are related with poor prognosis. Our aim was to analyze the benefits of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis due to uterine cancer.
METHODS
METHODS
At the Istanbul Umraniye Training and Research Hospital, Surgical Oncology Clinic, morbidity, overall survival and survival without progression were analyzed over the 5-year follow up. Twenty-two cases who had undergone cytoreductive surgery and hyperthermic intraperitoneal chemotherapy due to uterine-peritoneal carcinomatosis were included in this study. Cases were followed up in terms of postoperative morbidity-mortality, disease-free survival and overall survival. The cut off value for the peritoneal carcinomatosis index score was set at 15. Intraperitoneal chemotherapy consisting of cisplatin and doxorubicin was applied to all patients for 60 min after the suturation of the abdomen.
RESULTS
RESULTS
Median age of the patients was 64.6 (43-72). Average PCI score was 12.8 (3-15). CC score was 0 in 16 (72.7%) cases, 1 in 3 cases and 2 in 3 cases. Of these patients, 12 of them were previously operated upon. Median stay at the hospital was 13.1 days. No major complications due to chemotherapy were reported. A Clavien-Dindo Grade 3 complication was observed in seven (31.8%) patients. Mortality was not observed in patients during their stay at the hospital. The 5-year disease-free survival and overall survival rates were 36.8 (36%) months and 45.3 (57%) months, respectively.
CONCLUSIONS
CONCLUSIONS
We think that due to longer disease-free survival and overall survival, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be preferred in peritoneal carcinomatosis due to uterine cancer patients having low peritoneal carcinomatosis index scores and manageable complication rates. However, prospective randomizedtrials with a high number of cases are needed for this subject.
Identifiants
pubmed: 36579503
pii: jpm12111790
doi: 10.3390/jpm12111790
pmc: PMC9693328
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Anticancer Res. 2013 Mar;33(3):1041-4
pubmed: 23482779
BMC Surg. 2022 Jan 7;22(1):1
pubmed: 34996419
Gynecol Oncol Rep. 2015 Jul 02;13:60-3
pubmed: 26425725
J Surg Oncol. 2010 Jun 15;101(8):713-24
pubmed: 20512948
J Gynecol Oncol. 2019 Mar;30(2):e18
pubmed: 30806045
Surg Oncol. 2020 Jun;33:19-23
pubmed: 32561085
Gynecol Obstet Fertil Senol. 2017 Dec;45(12):715-725
pubmed: 29132772
Ann Surg Oncol. 2010 Dec;17(12):3220-8
pubmed: 20585874
Int J Gynecol Cancer. 2010 Jul;20(5):809-14
pubmed: 20973274
N Engl J Med. 2018 Jan 18;378(3):230-240
pubmed: 29342393
Eur J Obstet Gynecol Reprod Biol. 2014 Jan;172:111-4
pubmed: 24300558
Int J Gynecol Cancer. 2018 Jul;28(6):1130-1137
pubmed: 29975291
Ann Saudi Med. 2014 Mar-Apr;34(2):159-66
pubmed: 24894786
Obstet Gynecol. 2010 Nov;116(5):1141-9
pubmed: 20966700
World J Crit Care Med. 2017 May 4;6(2):116-123
pubmed: 28529913
Curr Treat Options Oncol. 2018 Nov 9;19(12):73
pubmed: 30411170
Ann Surg Oncol. 2018 Mar;25(3):679-687
pubmed: 29282600
Int J Gynecol Cancer. 2007 Jan-Feb;17(1):204-9
pubmed: 17291254
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43
pubmed: 17161155
Clin Exp Metastasis. 2019 Aug;36(4):321-329
pubmed: 31089843